Seasoned operating executive and investor focused on growth-stage technology and healthcare companies. Brad McFadden brings experience across corporate finance, M&A and portfolio management, combining hands-on operational leadership with capital allocation discipline. Known for scaling commercial teams, executing strategic carve-outs and supporting board governance, he works with private equity sponsors and venture funds to accelerate exits and value creation. Active in deal sourcing, due diligence and post-acquisition integration.
Seasoned operating executive and investor focused on growth-stage technology and healthcare companies. Brad McFadden brings experience across corporate finance, M&A and portfolio management, combining hands-on operational leadership with capital allocation discipline. Known for scaling commercial teams, executing strategic carve-outs and supporting board governance, he works with private equity sponsors and venture funds to accelerate exits and value creation. Active in deal sourcing, due diligence and post-acquisition integration.
Combines operational leadership with disciplined capital allocation to back growth-stage technology and healthcare companies, prioritizing commercial scale, repeatable go-to-market models and clear exit pathways. Favors control-oriented minority investments and sponsor-backed carve-outs where active governance, sales scaling and integration expertise accelerate value. Underwrites with operational KPIs, margin expansion potential and predictable cash conversion, applying a 3–7 year horizon for value realization. Risk is managed through staged funding, board-level oversight and alignment with private equity or venture partners to de-risk commercialization and optimize timing of strategic sale or recapitalization.
Combines operational leadership with disciplined capital allocation to back growth-stage technology and healthcare companies, prioritizing commercial scale, repeatable go-to-market models and clear exit pathways. Favors control-oriented minority investments and sponsor-backed carve-outs where active governance, sales scaling and integration expertise accelerate value. Underwrites with operational KPIs, margin expansion potential and predictable cash conversion, applying a 3–7 year horizon for value realization. Risk is managed through staged funding, board-level oversight and alignment with private equity or venture partners to de-risk commercialization and optimize timing of strategic sale or recapitalization.
| Trades 588 | Longs Won 408/588 69% | Profit Factor 6.83 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $392,786.16 |
| Average Win $163,122.4 | Best Trade (Jul 16) $3.73M | Sharpe Ratio -78.31 |
| Average Loss -$54,150.56 | Worst Trade (Jul 14) -$2.1M | Z-Score 8.04 (100%) |
| Commissions $0 | Avg. Trade Length 1y 3m 2w 4d | Expectancy $96,610.27 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 3,165 | 2,848 | 2,532 | 2,215 | 1,899 | 1,582 | 1,266 | 949 | 633 | 316 |